Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled and Active-controlled Trial to Evaluate the Effect of a Supratherapeutic Dose of MK-8527 on the QTc Interval in Healthy Adult Participants

Next Previous
Trial Profile

A Double-Blind, Placebo-Controlled and Active-controlled Trial to Evaluate the Effect of a Supratherapeutic Dose of MK-8527 on the QTc Interval in Healthy Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK-8527 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 29 Jan 2026 Status changed from active, no longer recruiting to completed.
  • 17 Dec 2025 Planned End Date changed from 15 Dec 2025 to 23 Dec 2025.
  • 09 Oct 2025 Planned End Date changed from 25 Nov 2025 to 15 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top